GIBSON DUNN

Gibson Dunn Advised LifeSci Capital as Financial Advisor in Quince Therapeutics' Acquisition of Orphai Therapeutics and Concurrent Private Placement Financing

Firm News | May 20, 2026

Gibson Dunn advised LifeSci Capital as financial advisor in Quince Therapeutics, Inc.'s acquisition of Orphai Therapeutics Inc. and concurrent private placement financing.

The Gibson Dunn corporate team included partners Ryan Murr and Branden Berns.

Related People

Ryan A. Murr

Branden C. Berns

Related Capabilities

Life Sciences

Mergers and Acquisitions

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**